Preoperative Butyrylcholinesterase Level as an Independent Predictor of Overall Survival in Clear Cell Renal Cell Carcinoma Patients Treated with Nephrectomy

Table 2

Relationship between clinical factors and overall survival in clear cell renal cell carcinoma.

Variable	Number of patients	Three-year overall survival rate (%)	95% CI	P value
Performance status
0	368	89.9	198.6–248.9	0.003
≥1	32	72.9	77.5–151.1
Gender
Male	286	88.4	157.3–196.9	0.596
Female	114	85.8	217.2–267.1
Hemoglobin
≥LLN	329	92.1	191.8–250.9	0.004
<LLN	71	72.9	152–215
Albumin
≥LLN	282	90.3	188–254.1	0.010
<LLN	118	81.5	153.2–206.8
BChE
≥100 U/L	356	89.3	194.6–251.6	0.004
<100 U/L	44	77.7	101.6–154.8
NLR
≤2.5	287	90.2	187.5–244.0	0.457
>2.5	113	81.6	114.3–174.1
Corrected calcium
≤10 mg/dL	383	89.0	195.8–245.5	0.007
>10 mg/dL	17	64.5	65.5–155.8
LDH
≤1.5 × ULN	396	88.0	196.3–241.9	0.551
>1.5 × ULN	4	75.0	42.5–86.7
C-reactive protein
≤0.3 mg/dL	281	93.0	219.4–265.6	<0.001
>0.3 mg/dL	119	76.4	116.8–175.6
T stage
T1	261	93.0	233.8–274.3	<0.001
T2	41	88.6	101.1–22.6
T3	88	74.4	126.1–181.3
T4	10	77.1	36.9–71.6
N stage
N0	386	89.4	198.4–244.9	0.001
N1	14	45.3	36.7–100.7
M stage
M0	344	93.4	187.3–232.1	<0.001
M1	56	57.9	82.1–167.5

CI: confidence interval; BChE: butyrylcholinesterase; LDH: lactate dehydrogenase; NLR: neutrophil-lymphocyte ratio; LLN: lower limit of laboratory’s normal range; ULN: upper limit of laboratory’s normal range; TNM: tumor-node-metastasis staging.